Efficacy of tipiracil/trifluridine (TAS-102) in patients with refractory metastatic colorectal cancer

Trial Profile

Efficacy of tipiracil/trifluridine (TAS-102) in patients with refractory metastatic colorectal cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary) ; Regorafenib
  • Indications Colorectal cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 May 2017 New trial record
    • 01 May 2017 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top